With its unique antibody-based technology, Confo Therapeutics aims to overcome the current limitations of GPCR drug discovery in order to fully realize the potential of GPCRs as drug targets.
Our drug discovery engine uses advanced antibody technology, ConfoBodies, to enable superior and more efficient drug discovery for dynamic membrane proteins in their natural environment.
A ConfoBody is a single-domain antibody (V HH ), generated using our proprietary processes, that binds to and stabilizes the protein in its therapeutically relevant conformation, for example in the agonist-bound active state. Our team has over 10 years of experience in ConfoBody discovery, employing a suite of V HH discovery techniques.